Involvement of TRPC5 Channels, Inwardly Rectifying K Channels, PLCβ and PIP in Vasopressin-mediated Excitation of Medial Central Amygdala Neurons
Overview
Affiliations
Activation of V vasopressin receptors facilitates neuronal excitability in the medial nucleus of central amygdala (CeM) V receptor activation excites about 80% CeM neurons by opening a cationic conductance and about 20% CeM neurons by suppressing an inwardly rectifying K (Kir) channel The cationic conductance activated by V receptors is identified as TRPC5 channels PLCβ-mediated depletion of PIP is involved in V receptor-elicited excitation of CeM neurons Intracellular Ca release and PKC are unnecessary for V receptor-mediated excitation of CeM neurons ABSTRACT: Arginine vasopressin (AVP) serves as a hormone in the periphery to modulate water homeostasis and a neuromodulator in the brain to regulate a diverse range of functions including anxiety, social behaviour, cognitive activities and nociception. The amygdala is an essential brain region involved in modulating defensive and appetitive behaviours, pain and alcohol use disorders. Whereas activation of V receptors in the medial nucleus of the central amygdala (CeM) increases neuronal excitability, the involved ionic and signalling mechanisms have not been determined. We found that activation of V receptors in the CeM facilitated neuronal excitability predominantly by opening TRPC5 channels, although AVP excited about one fifth of the CeM neurons via suppressing an inwardly rectifying K (Kir) channel. G proteins and phospholipase Cβ (PLCβ) were required for AVP-elicited excitation of CeM neurons, whereas intracellular Ca release and the activity of protein kinase C were unnecessary. Prevention of the depletion of phosphatidylinositol 4,5-bisphosphate (PIP ) blocked AVP-induced excitation of CeM neurons, suggesting that PLCβ-mediated depletion of PIP is involved in AVP-mediated excitation of CeM neurons. Our results may provide a cellular and molecular mechanism to explain the anxiogenic effects of AVP in the amygdala.
Francesconi W, Olivera-Pasilio V, Berton F, Olson S, Chudoba R, Monroy L bioRxiv. 2024; .
PMID: 39282380 PMC: 11398521. DOI: 10.1101/2024.09.06.611656.
Kola P, Oraegbuna C, Lei S Mol Cell Neurosci. 2024; 130:103951.
PMID: 38942186 PMC: 11401767. DOI: 10.1016/j.mcn.2024.103951.
Boyle C, Lei S J Cell Physiol. 2023; 238(6):1381-1404.
PMID: 37186390 PMC: 10330072. DOI: 10.1002/jcp.31020.
Calcium signaling in neurodevelopment and pathophysiology of autism spectrum disorders.
Pourtavakoli A, Ghafouri-Fard S Mol Biol Rep. 2022; 49(11):10811-10823.
PMID: 35857176 DOI: 10.1007/s11033-022-07775-6.
Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases.
Yeo X, Cunliffe G, Ho R, Lee S, Jung S Biomedicines. 2022; 10(2).
PMID: 35203552 PMC: 8961788. DOI: 10.3390/biomedicines10020343.